Loading…
← CockpitCompetitor Analysis › 4728.TWO SunMax Biotechnology Co. Ltd.Open in the cockpit ↗

SunMax Biotechnology Co. Ltd.4728.TWOCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Medical Specialties
Momentum leader 81
Mkt cap
$630M
US dollars, full cap
Free float
89%
of shares outstanding
$/day
$211,196
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+118.0 pp
WACC 5.0%
Hurdle
-21 pp
Req g minus delivered
Close · TWDNT$384.50
1Dn/a
1W-1.5%
1M-2.5%
3M+2.4%
6M0.0%
YTD-2.9%
1Y-6.9%
ATR %1.7%
52w lowhigh10.4% off high

What SunMax Biotechnology does

No business profile yet.

SunMax Biotechnology at a glance

Size SunMax Biotechnology (4728.TWO) is a Taiwan Health Care company (Medical Specialties) with a market value of $630M, the 359th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$384.50 on 18 Nov 2026.

Performance Over six months the shares was unchanged, against -9.3% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 8th highest of 19 in its peer set.

Growth Revenue grew 18.9% over the last twelve months (peer median +16.2%); the operating margin is 51.0% (peer median 9.5%).

Valuation It trades at 8.3× enterprise value to sales against a peer median of 3.8× (4th most expensive of 20).

Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -21 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 118.0 points above its cost of capital (5.0% WACC).

Relative performance

9010021 May 202621 Aug 202618 Nov 20264728.TWO 100Peer median 92
Six months, rebased to 100: SunMax Biotechnology against the median of its 20 peers (local-currency closes).

SunMax Biotechnology financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$2.37BNT$2.03BNT$1.82BNT$1.69BNT$1.40B
Revenue growth—+11%+8%+21%—
Gross profitNT$1.85BNT$1.55BNT$1.44BNT$1.36BNT$1.15B
EBITDANT$1.33BNT$1.10BNT$1.03BNT$967MNT$826M
Net incomeNT$898MNT$726MNT$679MNT$626MNT$534M
Free cash flowNT$959MNT$766MNT$534MNT$743MNT$494M
Capital expenditureNT$101MNT$79.0MNT$39.7MNT$140MNT$155M
Total debtNT$108MNT$119MNT$145MNT$174MNT$70.3M

Quarterly statements and history in the cockpit →

SunMax Biotechnology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%+20%18581789XVIVOQDELSNT300326NANMEDISGHTTCMD300314OBIO002876DCTH4910004728.TWO6-month return →1-month return →
Up and to the right = strong over both horizons. SunMax Biotechnology is the large dot.

Fundamentals: revenue growth against valuation

0%+250%+500%+750%+1,000%5×10×15×18581789XVIVOQDEL300326MEDISGHTVVVVOBIO4910004728.TWORevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. SunMax Biotechnology is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%18581789XVIVOSNT300326NANMEDITCMD688581DCTH4728.TWOGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. SunMax Biotechnology is the large dot.

SunMax Biotechnology competitors and peer comparison

How SunMax Biotechnology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

SunMax Biotechnology against its 20 peers (data as of 18 Nov 2026)
Measure4728.TWOPeer medianRank in peer set
1-month return-2.5%-0.1%8th lowest of 19
6-month return0.0%-9.3%8th highest of 19
Distance from 52-week high-10.4%-26.0%5th highest of 20
Revenue growth (TTM)+18.9%+16.2%8th highest of 20
Operating margin51.0%9.5%highest of 20
EV / Sales8.3×3.8×4th most expensive of 20
Growth the price implies (Req g, 7 yrs)-2.6%7.5%3rd least demanding of 13
Growth delivered (Del g)+18.8%+13.7%5th highest of 13
Hurdle (Req g minus delivered)-21.5 pp-7.5 pp4th least demanding of 13
ROIC minus cost of capital+118.0 pp+2.0 pphighest of 19
EV / EBITDA14.9×17.7×5th cheapest of 9
Net debt / EBITDA-0.7×-1.2×4th most indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
SunMax Biotechnology 4728.TWOTaiwan$630M0%+19%51%8.3×-2.6%+18.8%
Beijing Chunlizhengda Medical Instruments 1858.HKHong Kong$631M-28%-9%31%2.3×-9.5%+1.5%
AK Medical 1789.HKHong Kong$642M-23%+16%26%2.1×-11.5%+6.7%
Xvivo Perfusion XVIVO.STSweden$611M-32%+18%12%6.3×35.9%+35.2%
QuidelOrtho QDELUnited States$657M-20%-5%-2%1.4×n/an/a
Synektik SNT.WAPoland$662M+10%+32%24%2.9×0.2%+47.5%
Shanghai Kinetic Medical 300326.SZChina$662M-10%-28%17%3.8×6.6%-1.9%
Nanosonics NAN.AXAustralia$599M-4%+3%7%3.8×35.3%+6.7%
Medistim MEDI.OLNorway$599M+32%+19%29%7.1×-1.2%+14.5%
Sight Sciences SGHTUnited States$599M+122%+16%-30%6.4×n/an/a
Sahajanand Medical Technologies SMT.NSIndia$595Mn/an/an/an/an/an/a
vVARDIS VVVVUnited States$594Mn/a+148%-72%14.3×n/an/a
Tactile Systems Technology TCMDUnited States$592M+6%+14%9%1.5×8.4%+12.0%
Hangzhou AGS MedTech 688581.SSChina$590M-22%-18%33%3.7×0.4%+27.8%
Ningbo David Medical Device 300314.SZChina$589M+25%+19%11%5.4×n/an/a
Orchestra BioMed OBIOUnited States$587M+87%+1,007%-195%18.3×n/an/a
Shenzhen Sunnypol Optoelectornics 002876.SZChina$680M-9%+29%5%1.6×10.1%+14.2%
Delcath Systems DCTHUnited States$685M+75%+38%5%5.3×33.4%+120.2%
Livsmed 491000.KSSouth Korea$687M-47%+89%-77%18.1×n/an/a
Jiangsu Hanvo Safety Product 300952.SZChina$575M-38%+6%8%3.3×n/an/a
Shenzhen Lifotronic Technology 688389.SSChina$692M-14%+14%13%3.0×11.6%+13.3%

Questions

Which companies are SunMax Biotechnology's closest peers?
The cockpit's peer set: Beijing Chunlizhengda Medical Instruments (1858.HK), AK Medical (1789.HK), Xvivo Perfusion (XVIVO.ST), QuidelOrtho (QDEL), Synektik (SNT.WA), Shanghai Kinetic Medical (300326.SZ), Nanosonics (NAN.AX), Medistim (MEDI.OL).
Is SunMax Biotechnology expensive compared with its peers?
On ev / sales it trades at 8.3× against a peer median of 3.8×, 4th most expensive of 20 in its peer set. For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -21 pp: the price already allows for a slowdown.
How has SunMax Biotechnology stock performed?
Over six months to 18 Nov 2026 the shares returned 0.0% against -9.3% for the median peer; over one year -6.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.